Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

21.9%

7 terminated/withdrawn out of 32 trials

Success Rate

75.9%

-10.6% vs industry average

Late-Stage Pipeline

16%

5 trials in Phase 3/4

Results Transparency

77%

17 of 22 completed trials have results

Key Signals

1 recruiting17 with results4 withdrawn

Enrollment Performance

Analytics

Phase 2

16(59.3%)

Phase 1

6(22.2%)

Phase 3

5(18.5%)

27Total

Phase 2(16)

Phase 1(6)

Phase 3(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (32)

Showing 20 of 32 trials

NCT06117306Phase 3Recruiting

MDMA-assisted Massed Prolonged Exposure for PTSD

Role: collaborator

NCT04060108Completed

Stanford Regulating Circuits of the Brain Study - MDMA

Role: collaborator

NCT05979844Phase 3Completed

MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD

Role: collaborator

NCT04784143Phase 2Terminated

Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD

Role: lead

NCT03485287Phase 2Completed

Study of Safety and Effects of MDMA-assisted Psychotherapy for Treatment of PTSD (Canada)

Role: lead

NCT00090064Phase 2Completed

MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder

Role: lead

NCT04714359Phase 3Completed

A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD

Role: lead

NCT03537014Phase 3Completed

A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)

Role: lead

NCT04077437Phase 3Completed

A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)

Role: lead

NCT01689740Phase 2Completed

Randomized, Double-blind, Placebo-Controlled Pilot Study of MDMA-assisted Therapy for PTSD

Role: lead

NCT01211405Phase 2Completed

Study Comparing Three Doses of MDMA Along With Therapy in Veterans With Posttraumatic Stress Disorder

Role: lead

NCT00402298Phase 2Terminated

Randomized Placebo-controlled Study of MDMA-assisted Therapy in People With PTSD - Israel

Role: lead

NCT01958593Phase 2Terminated

Randomized, Double-blind, Controlled of MDMA-assisted Psychotherapy in 12 Subjects With PTSD

Role: lead

NCT03282123Phase 2Completed

Open Label Multi-Site Study of Safety and Effects of MDMA-assisted Therapy for Treatment of PTSD

Role: lead

NCT02008396Phase 2Completed

Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults

Role: lead

NCT02427568Phase 2Completed

MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness

Role: lead

NCT01793610Phase 2Completed

Dose-Response Study of MDMA-assisted Psychotherapy in People With PTSD

Role: lead

NCT02876172Phase 1Completed

MDMA-Assisted Cognitive-Behavioral Conjoint Therapy (CBCT) in Dyads in Which 1 Member Has Chronic PTSD

Role: lead

NCT03181763Phase 1Completed

Evaluation of MDMA on Startle Response

Role: lead

NCT04438512Unknown

A Multi-site Expanded Access Program for MDMA-assisted Psychotherapy for Patients With Treatment-resistant PTSD

Role: lead